The global pharmaceutical industry experienced a 69% drop in company filings mentions of COVID-19 in Q4 2023 compared with the previous quarter, with the highest share accounted for by Moderna with 27% year-on-year increase, according to GlobalData’s analysis of over 768 pharmaceutical company filings. GlobalData’s Pharma: Filings Trends & Signals Q4 2023 report delves into earnings call transcripts and quarterly reports within the pharmaceuticals industry, extracting trends, signals, and comparative data to help businesses assess their performance, identify competitive intelligence, evaluate risks, and gain a comprehensive understanding of key industry events. Buy the report here.
Notably, COVID-19 was one of the most frequently referenced themes in Q4 2023, ranking highest in terms of mentions, ahead of individualism & expression and personalization, according to GlobalData.
Of the top leading companies in the pharmaceutical industry, Moderna had the greatest increase in references for COVID-19 in Q4 2023, compared with the previous quarter. GlobalData identified 201 COVID-19-related sentences in the company's filings - 19% of all sentences - and an increase of 27% in Q4 2023 compared with Q4 2022. GSK’s mentions of COVID-19 dropped by 27% to 83 and Pfizer’s by 67% to 83 and F. Hoffmann-La Roche’s by 11% to 62 and Merck’s by 32% to 54.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for COVID-19 in Q4 2023 was 173.
For further understanding of GlobalData's Pharma: Filings Trends & Signals Q4 2023, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.